In today's pre-market trading session, ALEBUND-B (09637), often referred to as the first kidney disease innovation drug stock on the Hong Kong market, closed at HK$43.88. This represents a significant gain of 94.16% over its issue price of HK$22.60.

For each board lot of 100 shares, investors stand to make a paper profit of HK$2,128, excluding transaction fees.

The company's initial public offering has captured significant market attention. It boasts a robust pipeline with one commercialized product and seven clinical-stage drug candidates. Furthermore, it has secured a strong lineup of 11 cornerstone investors, including global sovereign wealth funds, century-old asset managers, specialized life sciences funds, and industrial capital, setting a new benchmark for cornerstone investor participation in recent years for companies listed under Chapter 18A.

ALEBUND-B is scheduled to commence trading on the Hong Kong Stock Exchange on Monday, June 29th.